NEJM EvidenceEnoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients

VTE affects 1.6 out of 1000 people annually, with hospitalization being a key risk factor.

The SYMPTOMS trial was a prospective, randomized, placebo-controlled, multicenter, international study designed to evaluate the efficacy of low-molecular-weight heparin in preventing symptomatic venous thromboembolism (VTE) in older adults hospitalized for acute medical conditions.

Key Points:

• The SYMPTOMS trial was performed with older adults (70 years or older) hospitalized for acute medical conditions.
• The trial employed a randomized, placebo-controlled design to assess the efficacy of low-molecular-weight heparin.
• The primary efficacy outcome was symptomatic confirmed VTE or fatal pulmonary embolism through day 30.
• There was no significant difference observed in the primary efficacy outcome between the enoxaparin and placebo groups.

Additional Points:

• The median age of participants was 82 years.
• The median duration of trial drug administration was 7 days.
• The secondary efficacy outcome, symptomatic confirmed VTE or fatal pulmonary embolism through day 90, saw a slightly lower incidence in the enoxaparin group.
• Major bleeding, the primary safety outcome, occurred in 0.9% of patients in the enoxaparin group and 1.0% of patients in the placebo group.

Conclusion:

• The SYMPTOMS trial did not find a significant difference in the incidence of symptomatic VTE or fatal pulmonary embolism in older adults hospitalized for acute medical conditions between those treated with enoxaparin and those given a placebo. The safety profile was comparable between the two groups.

Hematology Latest Posts

• A Popular Low Calorie Sweetener May Raise the Risk of Blood ClottingOctober 28, 2024
• Abdominal Pain in a Patient with Epistaxis, Telangiectasias, and Arteriovenous MalformationsOctober 28, 2024
• Is Luspatercept the New Standard of Care in Transfusion-Dependent Low-Risk Myelodysplastic Syndromes?October 21, 2024
• Combination Ponatinib Plus Blinatumomab Shows High Efficacy in Ph-Positive ALLAugust 26, 2024

Did You Know?
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is considered the third most common cardiovascular illness after acute coronary syndrome and stroke